JAX Clinical Genomics delivers comprehensive molecular interpretation resources and precise genomic profiling services to improve patient care. Our Clinical Knowledgebase (CKB) is the standard in evidence-based interpretation of complex cancer genomic profiles. It contains up-to-date information on variants, literature, preclinical data, FDA drug labels, targeted therapies, and clinical trials related to more than 1,800 genes.
The CLIA-certified, CAP-accredited, and NCI-MATCH-designated Advanced Precision Medicine Laboratory features the latest sequencing and PCR technologies. Our test menu includes our proprietary JAX OncoMethyl™ Array, a comprehensive methylome profiling technique for CNS tumors, the JAX SOMASEQ™ test, an assay used for predicting response to treatment, and the JAX MGMT Promoter Methylation Assay, a predictor for temozolomide treatment in CNS tumors.
For the past 90+ years, the Jackson Laboratory has been a significant force in genetic discovery. We remain focused on using our expertise and resources to help oncologists and translational researchers identify relevant biomarkers, interpret complex genomic profiles, design clinical trials, and select the best treatment options for each patient.
The Hartford Business Journal has recognized JAX among its 2020 Health Care Heroes in the Innovation category, recognizing an organization that has made a positive advancement in medical care or medical science.